艾司西酞普兰联合舒肝解郁胶囊对老年抑郁症伴失眠的影响

doi:10.3760/cma.j.cn441417-20241125-09027

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (9): 1549-1553.DOI: 10.3760/cma.j.cn441417-20241125-09027

艾司西酞普兰联合舒肝解郁胶囊对老年抑郁症伴失眠的影响

杨玉凤¹ 卢立军¹ 邓倩² 陈士东² 王慧颖³

¹南阳医学高等专科学校第一附属医院药学部，南阳 473000；²南阳医学高等专科学校第一附属医院神经内科，南阳 473000；³新乡医学院第二附属医院精神神经研究所，新乡 453000

收稿日期:2024-11-25 出版日期:2025-05-01 发布日期:2025-05-20
通讯作者: 杨玉凤，Email：fanhuasijin456789@163.com
基金资助:
河南省科技发展计划（222102310555）

Effect of escitalopram combined with Shugan Jieyu capsule on senile depression with insomnia

Yang Yufeng¹, Lu Lijun¹, Deng Qian², Chen Shidong², Wang Huiying³

¹Department of Pharmacy, The First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China; ²Department of Neurology, The First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China; ³Institute of Psychiatry and Neurology, The Second Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, China

Received:2024-11-25 Online:2025-05-01 Published:2025-05-20
Contact: Yang Yufeng, Email:fanhuasijin456789@163.com
Supported by:
Henan Science and Technology Development Plan (222102310555)

摘要/Abstract

摘要：

目的　分析艾司西酞普兰联合舒肝解郁胶囊治疗老年抑郁症伴失眠患者的疗效。方法　回顾性选取2021年5月至2023年5月南阳医学高等专科学校第一附属医院收治的老年抑郁症伴失眠的门诊患者58例，按照治疗方法不同分为对照组和观察组，每组29例。对照组男12例、女17例，年龄（68.79±3.26）岁，病程（12.57±2.45）月；采用艾司西酞普兰治疗，口服，初期剂量10 mg/d，并在2周内调整剂量至20 mg/d。观察组男14例、女15例，年龄（69.52±3.35）岁，病程（12.82±2.34）月；在对照组基础上联合舒肝解郁胶囊治疗，口服，0.72 g/次，2次/d。所有患者均连续治疗2个月。对比两组临床疗效、心理状态［抑郁自评量表（SDS）、焦虑自评量表（SAS）评分］、睡眠指标（入睡时间、睡眠时间）、蒙特利尔认知评估量表（MoCA）评分、神经功能指标［5-羟色胺（5-HT）、多巴胺（DA）、去甲肾上腺素（NE）］、匹兹堡睡眠质量指数量表（PSQI）评分、生活质量综合评定问卷（GQOLI-74）评分、不良反应。采用Fisher精确概率检验、t检验进行统计分析。结果　观察组治疗总有效率高于对照组［96.55%（28/29）比72.41%（21/29）］，差异有统计学意义（P=0.025）。治疗2个月后，观察组的SDS、SAS评分均低于对照组［（32.45±2.12）分比（38.26±2.43）分、（31.64±1.93）分比（37.58±2.12）分］；观察组入睡时间比对照组短［（30.58±3.24）min比（54.62±4.35）min］，睡眠时间比对照组长［（6.71±1.35）h比（5.26±1.21）h］，MoCA评分高于对照组［（28.23±1.04）分比（25.76±1.15）分］；观察组的5-HT、DA、NE分别为（108.51±6.35）µg/L、（78.26±4.18）ng/L、（10.12±0.64）mg/L］，对照组上述指标分别为（98.76±5.02）µg/L、（66.58±3.75）ng/L、（9.35±0.58）mg/L；观察组的PSQI评分低于对照组［（4.72±0.53）分比（7.25±0.62）分］，GQOLI-74评分高于对照组［（78.29±4.38）分比（70.35±4.12）分］；差异均有统计学意义（均P<0.05）。两组不良反应总发生率差异无统计学意义（P=1.000）。结论　艾司西酞普兰联合舒肝解郁胶囊治疗老年抑郁症伴失眠患者，可提高临床疗效，减轻抑郁症状，延长睡眠时间，改善认知功能，调节神经递质水平，改善睡眠质量，提高生活质量，且安全性较佳。

关键词: , 抑郁症, , , 失眠, , , 老年人, , , 艾司西酞普兰, , , 舒肝解郁胶囊

Abstract:

Objective　To analyze the efficacy of escitalopram combined with Shugan Jieyu capsule in the treatment of senile depression with insomnia. Methods　A total of 58 outpatients with senile depression and insomnia admitted to the First Affiliated Hospital of Nanyang Medical College from May 2021 to May 2023 were retrospectively selected and divided into control group and observation group according to different treatment methods, with 29 cases in each group. In the control group, there were 12 males and 17 females, aged (68.79±3.26) years old, and the course of disease was (12.57±2.45) months. The patients were treated with escitalopram orally, with an initial dose of 10 mg/d, and the dose was adjusted to 20 mg/d within 2 weeks. There were 14 males and 15 females in the observation group, aged (69.52±3.35) years old, and the course of disease was (12.82±2.34) months. Patients in the control group were po administered with Shugan Jieyu Capsules on the basis of the control group, 0.72 g/d, 2 times/d. All patients were treated continuously for 2 months.Clinical efficacy, psychological status [Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS) scores], sleep indicators (sleep onset time, total sleep time), Montreal Cognitive Assessment (MoCA) scores, neurochemical indicators [serotonin (5-HT), dopamine (DA), norepinephrine (NE)], Pittsburgh Sleep Quality Index (PSQI) scores, General Quality of Life Inventory (GQOLI-74) scores, and adverse reactions were compared between the two groups. Statistical analyses were performed using Fisher's exact test and t tests. Results　The total effective rate in the observation group was higher than that in the control group [96.55% (28/29) vs. 72.41% (21/29)], with a statistically significant difference (P=0.025). After 2 months of treatment, the SDS and SAS scores in the observation group were lower than those in the control group [(32.45±2.12) points vs. (38.26±2.43) points, (31.64±1.93) points vs. (37.58±2.12) points]. The observation group had a shorter sleep onset time compared to the control group [(30.58±3.24) min vs. (54.62±4.35) min] and a longer total sleep time [(6.71±1.35) h vs. (5.26±1.21) h]. The MoCA score in the observation group was higher than that in the control group [(28.23±1.04) points vs. (25.76±1.15) points]. The levels of 5-HT, DA, and NE in the observation group were (108.51±6.35) µg/L, (78.26±4.18) ng/L, and (10.12±0.64) mg/L, respectively, compared to (98.76±5.02) µg/L, (66.58±3.75) ng/L, and (9.35±0.58) mg/L in the control group. The PSQI score in the observation group was lower than that in the control group [(4.72±0.53) points vs. (7.25±0.62) points], while the GQOLI-74 score was higher in the observation group [(78.29±4.38) points vs. (70.35±4.12) points], with all differences being statistically significant (all P<0.05). The overall incidence of adverse reactions between the two groups was not statistically significant (P=1.000). Conclusion　Escitalopram combined with Shugan Jieyu capsule in the treatment of senile depression with insomnia can improve the clinical efficacy and reduce depression, Prolong sleep time, improve cognitive function, regulate neurotransmitter levels, Improve sleep quality, improve quality of life, and better safety.

Key words: Depressive disorder, , Insomnia, , The aged, , Escitalopram oxalate, , Shugan Jieyu , capsule

杨玉凤卢立军邓倩陈士东王慧颖.

艾司西酞普兰联合舒肝解郁胶囊对老年抑郁症伴失眠的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1549-1553.

Yang Yufeng, Lu Lijun, Deng Qian, Chen Shidong, Wang Huiying.

Effect of escitalopram combined with Shugan Jieyu capsule on senile depression with insomnia [J]. International Medicine and Health Guidance News, 2025, 31(9): 1549-1553.

参考文献

[1]谢正,谢春雨,史晓红,等.甜梦口服液联合氟西汀治疗抑郁症的临床研究及对低动力症状的影响[J].中草药,2023,54(10):3216-3220. DOI:10.7501/j.issn.0253-2670.2023.10.019.

[2]余翔,黄忠飞,朱早晨.舒肝解郁胶囊联合艾司西酞普兰、阿戈美拉汀治疗中老年抑郁伴失眠患者的临床疗效观察[J].临床和实验医学杂志,2022,21(8):800-803. DOI:10.3969/j.issn.1671-4695.2022.08.005.

[3]包炤华,过婷,张凯,等.舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁症伴失眠疗效及作用机制[J].现代中西医结合杂志,2020,29(30):3385-3389. DOI:10.3969/j.issn.1008-8849.2020.30.019.

[4]孙毅,田国祥,石克威,等.舒肝解郁胶囊与草酸艾司西酞普兰治疗高血压合并焦虑、抑郁的对照研究[J].中国循证心血管医学杂志,2018,10(12):1478-1479,1487. DOI:10.3969/j.issn.1674-4055.2018.12.10.

[5]吕振华,范晓静,李文雯.舒肝解郁胶囊联合噻托溴铵减轻尘肺合并慢性阻塞性肺引起的抑郁症——评«中国药典2020年版四部通则»[J].中国实验方剂学杂志,2022,28(19):203.

[6]司夏樱,岳秀宁,王昕,等.舒肝解郁胶囊联合重复经颅磁刺激治疗对围绝经期抑郁神经内分泌功能的影响[J].中国实验方剂学杂志,2019,25(1):163-168. DOI:10.13422/j.cnki.syfjx.20190132.

[7]戴云飞,肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较[J].临床精神医学杂志,2013,23(6):426-427.

[8]王汝展,刘兰芬,葛红敏,等. ZUNG氏抑郁自评量表(SDS)作为外科住院患者抑郁障碍常规筛查工具的可行性研究[J].精神医学杂志,2009,22(4):251-253. DOI:10.3969/j.issn.1009-7201.2009.04.004.

[9]段泉泉,胜利.焦虑及抑郁自评量表的临床效度[J].中国心理卫生杂志,2012,26(9):676-679. DOI:10.3969/j.issn.1000-6729.2012.09.007.

[10]张立秀,刘雪琴.蒙特利尔认知评估量表中文版的信效度研究[J].护理研究,2007,21(31):2906-2907. DOI:10.3969/j.issn.1009-6493.2007.31.044.

[11]吴凌云,徐旭,马红梅.武汉市高龄老年人匹兹堡睡眠质量指数的调查分析[J].中国医药导报,2013,10(4):119-121. DOI:10.3969/j.issn.1673-7210.2013.04.046.

[12]郭克锋,郭珊,闫凯麟,等.抑郁症患者家庭功能缺陷及家属的生活质量调查[J].中国临床康复,2005,9(44):20-22. DOI:10.3321/j.issn:1673-8225.2005.44.007.

[13]Xiao M, Feng L, Wang Q, et al. The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression[J]. Int J Geriatr Psychiatry, 2021, 36(1): 182-189. DOI: 10.1002/gps.5412.

[14]鄢玲,李伟.舒肝解郁胶囊治疗阿尔茨海默病伴抑郁患者的临床疗效及对其氧化应激的影响[J].世界中西医结合杂志,2020,15(12):2261-2264. DOI:10.13935/j.cnki.sjzx.201222.

[15]Chang CH, Chou PH, Chuang HY, et al. Efficacy of non-invasive brain stimulation for treating depression in patients with traumatic brain injury: a meta-analysis and meta-regression of randomized controlled trials[J]. J Clin Med, 2023, 12(18): 6030. DOI: 10.3390/jcm12186030.

[16]慈轶宏,徐天朝,李冬冬,等.舒肝解郁胶囊联合阿戈美拉汀对抑郁症患者血清单胺类神经递质和神经功能相关因子的影响[J].现代生物医学进展,2022,22(12):2298-2302. DOI:10.13241/j.cnki.pmb.2022.12.020.

[17]Psaros C, Stanton AM, Raggio GA, et al. Optimizing PMTCT adherence by treating depression in perinatal women with hiv in south africa: a pilot randomized controlled trial[J]. Int J Behav Med, 2023, 30(1): 62-76. DOI: 10.1007/s12529-022-10071-z.

[18]胡晓蕊,沈宗霖,翟天柱,等.脑源性神经营养因子基因Val66Met多态性与首次发病未治疗抑郁症患者大脑灰质体积的关联研究[J].中华精神科杂志,2020,53(3):221-228. DOI:10.3760/cma.j.cn113661-20190919-00337.

[19]谭红阳,万建伟,许弄章.舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁疗效观察[J].陕西中医,2018,39(1):44-46. DOI:10.3969/j.issn.1000-7369.2018.01.014.

[20]张大伟,崔利,吴琼.舒肝解郁胶囊联合艾司西酞普兰治疗卒中后抑郁焦虑的疗效观察[J].航空航天医学杂志,2018,29(1):95-97. DOI:10.3969/j.issn.2095-1434.2018.01.049.

[21]杨娜,周红霞,任振勇,等.舒肝解郁胶囊联合西酞普兰对老年抑郁症患者情绪及认知功能的影响[J].国际精神病学杂志,2021,48(2):261-263.DOI:10.13479/j.cnki.jip.2021.02.020.

[22]苏少慧,刘洪娜,胡义亭,等.舒肝解郁胶囊治疗慢性乙型肝炎伴轻中度抑郁的临床效果及其对外周血淋巴细胞亚群的影响研究[J].中国全科医学,2018,21(3):330-333,337. DOI:10.3969/j.issn.1007-9572.2017.00.249.

[23]秦灵芝,李玮,王晓娟,等.艾司西酞普兰联合重复经颅磁刺激对脑出血伴抑郁症状患者工作记忆的影响[J].中华物理医学与康复杂志,2018,40(4):287-289. DOI:10.3760/cma.j.issn.0254-1424.2018.04.011.

[24]曾菊蓉,谢晓红,蒋慧,等.心理激励联合艾司西酞普兰干预对慢性阻塞性肺疾病伴焦虑患者心理状态的影响[J].中国健康心理学杂志,2023,31(2):186-191. DOI:10.13342/j.cnki.cjhp.2023.02.005.

[25]李婧,姚冠群,李曜均,等.舒肝解郁胶囊对轻中度抑郁症疗效的静息态功能磁共振低频振幅研究[J].中华行为医学与脑科学杂志,2024,33(4):303-309. DOI:10.3760/cma.j.cn371468-20230901-00082.

[26]王超,余葱葱,柯潇,等.基于"脏虚为本,气郁为标"理论抗抑郁中药舒肝解郁胶囊临床应用及作用机理研究进展[J].中药药理与临床,2023,39(4):120-124. DOI:10.13412/j.cnki.zyyl.2023.04.003.

艾司西酞普兰联合舒肝解郁胶囊对老年抑郁症伴失眠的影响

Effect of escitalopram combined with Shugan Jieyu capsule on senile depression with insomnia

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	赵洲刘为朋李宗睿王睿智胡宝光. 高血压大鼠模型的研究现状 [J]. 国际医药卫生导报, 2025, 31(9): 1465-1470.
[2]	吴亚莉付小平丁大为徐宁安周源源. 儿童注意缺陷多动障碍相关危险因素及预测模型构建 [J]. 国际医药卫生导报, 2025, 31(9): 1489-1494.
[3]	汪青园方元龙王智琴黄蓉田松原丽科葛午平朱小春肖尚杰周佳亮. 新生儿坏死性小肠结肠炎保守治疗后继发肠狭窄诊治分析 [J]. 国际医药卫生导报, 2025, 31(9): 1495-1498.
[4]	邓巧妮常亚娜周晓玉康华. 新生儿呼吸窘迫综合征机械通气撤机失败的预警模型构建 [J]. 国际医药卫生导报, 2025, 31(9): 1499-1505.
[5]	张森山蔡美孙锋. 新生儿ABO溶血病中血清总胆红素、脐血胆红素水平及网织红细胞计数对神经系统损害的预测价值 [J]. 国际医药卫生导报, 2025, 31(9): 1506-1510.
[6]	张珂刘景刚吴瑞荣冯慧. 局部枸橼酸钠联合小剂量肝素钠抗凝在脓毒症并急性肾损伤患者CRRT中的应用价值 [J]. 国际医药卫生导报, 2025, 31(9): 1516-1520.
[7]	臧柯靓班芳张秋梅张恒亮. 香丹注射液联合酒石酸美托洛尔对冠心病心绞痛患者临床症状及氧化应激反应的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1520-1524.
[8]	江正发王立友张晓徐宏勇. 药物涂层球囊成形术后冠心病患者靶血管再狭窄的危险因素研究及预测模型分析 [J]. 国际医药卫生导报, 2025, 31(9): 1525-1531.
[9]	潘希安张远金张国富李俊孙法瑞刘炳霞. 人工智能技术在膝单髁置换术前规划中的应用分析 [J]. 国际医药卫生导报, 2025, 31(9): 1532-1537.
[10]	张婷郭淋张驰付瑞崔治权康晓刚. 青少年双相情感障碍患者血脂水平与区域性脑结构的相关性研究 [J]. 国际医药卫生导报, 2025, 31(9): 1538-1543.
[11]	李岩赵丽敏曲姗姗. 帕罗西汀联合茴拉西坦治疗老年抑郁症的疗效分析 [J]. 国际医药卫生导报, 2025, 31(9): 1544-1548.
[12]	潘祁喻莉张安生. 铸瓷嵌体冠在短基牙后牙修复患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1554-1558.
[13]	陈春桃区秀丽李彩霞刘彩玲曾娜芬杜真萍蔡少娜米谦符霞. 维持性血液透析患者自体动静脉内瘘瘤样扩张防治不足影响因素的质性研究 [J]. 国际医药卫生导报, 2025, 31(9): 1559-1564.
[14]	陈娟娟. 中线导管在住院病区患者静脉治疗中的应用现状 [J]. 国际医药卫生导报, 2025, 31(9): 1565-1568.
[15]	魏欣妍魏文娟可易弘钱海兵. 基于授权赋能理论的健康教育在类风湿性关节炎患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1569-1573.